The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What’s new for the management of polycythemia vera?

During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Heinz Gisslinger, Medical University of Vienna, Vienna, AT. We asked, What’s new for the management of polycythemia vera (PV)?

What’s new for the management of polycythemia vera?

Recent years have seen progress in the management of PV in the form of lowering hematocrit levels and using aspirin to prevent thromboembolic events. Gisslinger discusses when and how to use cytoreductive therapy based on available data on ropeginterferon compared with hydroxyurea in PV.

Share: